Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122949273 | 12294927 | 3 | F | 20160401 | 20160902 | 20160422 | 20160914 | EXP | JP-ASTELLAS-2016US015453 | ASTELLAS | 55.48 | YR | F | Y | 0.00000 | 20160914 | CN | GB | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122949273 | 12294927 | 1 | PS | Erlotinib | ERLOTINIB | 1 | Oral | 750 | MG | Y | 21743 | 150 | MG | TABLET | QD | ||||
| 122949273 | 12294927 | 2 | SS | BEVACIZUMAB | BEVACIZUMAB | 1 | Intravenous drip | Y | 0 | 775 | MG | SOLUTION FOR INFUSION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 122949273 | 12294927 | 1 | Lung adenocarcinoma |
| 122949273 | 12294927 | 2 | Lung adenocarcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 122949273 | 12294927 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 122949273 | 12294927 | Febrile neutropenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 122949273 | 12294927 | 1 | 20160328 | 20160401 | 0 | |
| 122949273 | 12294927 | 2 | 20160328 | 20160401 | 0 |